Significant Unmet Needs in Oncology and Competition in New Drug Development
First written in FY2017-Q1. 24 of 25 entries say "Restated". Latest entry: FY2026.
0 other companies' latest entry also says "Restated".
- FY2026RestatedAnnual report
「The cancer field, where clinical treatment outcomes have room for improvement, continues to be regarded as one of the promising areas for targeting new drug development, and pharmaceutical companies and biotechnology ventures worldwide are working to strengthen their research and development capabilities.」
The unmet medical needs in oncology and competition in research and development between pharmaceutical companies and biotechnology ventures continue to define the business environment. - FY2025-H1RestatedAnnual report
「The field of anticancer drug development in which the company operates continues to have substantial unmet needs because clinical treatment outcomes remain unsatisfactory. Global pharmaceutical companies and drug-discovery ventures like the company are competing daily in research and development, seeking to develop innovative new drugs that capitalize on their respective strengths and distinctive capabilities.」
The company continues to identify the significant unmet needs in cancer and competition in research and development among pharmaceutical companies and drug-discovery ventures as part of its business environment. - FY2024-Q3RestatedAnnual report
「The field of anticancer drug development in which the company operates continues to have substantial unmet needs because clinical treatment outcomes remain unsatisfactory. Global pharmaceutical companies and drug-discovery ventures like the company are competing daily in research and development, seeking to develop innovative new drugs that capitalize on their respective strengths and distinctive capabilities.」
The company continues to identify the significant unmet needs in cancer and competition in research and development among pharmaceutical companies and drug-discovery ventures as part of its business environment. - FY2024-Q1RestatedAnnual report
「The field of anticancer drug development in which the company operates continues to have substantial unmet needs because clinical treatment outcomes remain unsatisfactory. Global pharmaceutical companies and drug-discovery ventures like the company are competing daily in research and development, seeking to develop innovative new drugs that capitalize on their respective strengths and distinctive capabilities.」
The company continues to identify the significant unmet needs in cancer and competition in research and development among pharmaceutical companies and drug-discovery ventures as part of its business environment. - FY2023-Q3RestatedAnnual report
「The field of anticancer drug development in which the company operates continues to have substantial unmet needs because clinical treatment outcomes remain unsatisfactory. Global pharmaceutical companies and drug-discovery ventures like the company are competing daily in research and development, seeking to develop innovative new drugs that capitalize on their respective strengths and distinctive capabilities.」
The company continues to identify the significant unmet needs in cancer and competition in research and development among pharmaceutical companies and drug-discovery ventures as part of its business environment. - FY2023-Q2RestatedAnnual report
「The field of anticancer drug development in which the company operates continues to have substantial unmet needs because clinical treatment outcomes remain unsatisfactory. Global pharmaceutical companies and drug-discovery ventures like the company are competing daily in research and development, seeking to develop innovative new drugs that capitalize on their respective strengths and distinctive capabilities.」
The company continues to identify the significant unmet needs in cancer and competition in research and development among pharmaceutical companies and drug-discovery ventures as part of its business environment. - FY2022RestatedAnnual report
「The cancer field, where clinical treatment outcomes have room for improvement, continues to be regarded as one of the promising areas for targeting new drug development, and pharmaceutical companies and biotechnology ventures worldwide are working to strengthen their research and development capabilities.」
The company continues to identify unmet needs in cancer and competition in research and development among pharmaceutical companies and biotechnology ventures as part of its business environment. - FY2022-Q3RestatedAnnual report
「The field of anticancer drug development in which the company operates continues to have substantial unmet needs because clinical treatment outcomes remain unsatisfactory. Global pharmaceutical companies and drug-discovery ventures like the company are competing daily in research and development, seeking to develop innovative new drugs that capitalize on their respective strengths and distinctive capabilities.」
The company continues to identify the significant unmet needs in cancer and competition in research and development among pharmaceutical companies and drug-discovery ventures as part of its business environment. - FY2022-Q2RestatedAnnual report
「The field of anticancer drug development in which the company operates continues to have substantial unmet needs because clinical treatment outcomes remain unsatisfactory. Global pharmaceutical companies and drug-discovery ventures like the company are competing daily in research and development, seeking to develop innovative new drugs that capitalize on their respective strengths and distinctive capabilities.」
The company continues to identify the significant unmet needs in cancer and competition in research and development among pharmaceutical companies and drug-discovery ventures as part of its business environment. - FY2021RestatedAnnual report
「The cancer field, where clinical treatment outcomes still have room for improvement, continues to be regarded as one of the promising areas for targeting new drug development, and pharmaceutical companies and biotechnology ventures worldwide are working to strengthen their research and development capabilities.」
The company continues to recognize unmet needs in cancer and competition in research and development among pharmaceutical companies and biotechnology ventures. - FY2021-Q3RestatedAnnual report
「The field of anticancer drug development in which the company operates continues to have substantial unmet needs because clinical treatment outcomes remain unsatisfactory. Global pharmaceutical companies and drug-discovery ventures like the company are competing daily in research and development, seeking to develop innovative new drugs that capitalize on their respective strengths and distinctive capabilities.」
The company continues to identify the significant unmet needs in cancer and competition in research and development among pharmaceutical companies and drug-discovery ventures as part of its business environment. - FY2021-Q2RestatedAnnual report
「The field of anticancer drug development in which the company operates continues to have substantial unmet needs because clinical treatment outcomes remain unsatisfactory. Global pharmaceutical companies and drug-discovery ventures like the company are competing daily in research and development, seeking to develop innovative new drugs that capitalize on their respective strengths and distinctive capabilities.」
The company continues to identify the significant unmet needs in cancer and competition in research and development among pharmaceutical companies and drug-discovery ventures as part of its business environment. - FY2021-Q1RestatedAnnual report
「The field of anticancer drug development in which the company operates continues to have substantial unmet needs because clinical treatment outcomes remain unsatisfactory. Global pharmaceutical companies and drug-discovery ventures like the company are competing daily in research and development, seeking to develop innovative new drugs that capitalize on their respective strengths and distinctive capabilities.」
The company continues to identify the significant unmet needs in cancer and competition in research and development among pharmaceutical companies and drug-discovery ventures as part of its business environment. - FY2020RestatedAnnual report
「The cancer field, where clinical treatment outcomes still have room for improvement, continues to be regarded as one of the promising areas for targeting new drug development, and pharmaceutical companies and biotechnology ventures worldwide are working to strengthen their research and development capabilities.」
The company continues to identify unmet needs in cancer and competition in research and development among pharmaceutical companies and biotechnology ventures as part of its business environment. - FY2020-Q3RestatedAnnual report
「The field of anticancer drug development in which the company operates continues to have substantial unmet needs because clinical treatment outcomes remain unsatisfactory. Global pharmaceutical companies and drug-discovery ventures like the company are competing daily in research and development, seeking to develop innovative new drugs that capitalize on their respective strengths and distinctive capabilities.」
The company continues to identify the significant unmet needs in cancer and competition in research and development among pharmaceutical companies and drug-discovery ventures as part of its business environment. - FY2020-Q2RestatedAnnual report
「The field of anticancer drug development in which the company operates continues to have substantial unmet needs because clinical treatment outcomes remain unsatisfactory. Global pharmaceutical companies and drug-discovery ventures like the company are competing daily in research and development, seeking to develop innovative new drugs that capitalize on their respective strengths and distinctive capabilities.」
The company continues to identify the significant unmet needs in cancer and competition in research and development among pharmaceutical companies and drug-discovery ventures as part of its business environment. - FY2020-Q1RestatedAnnual report
「The field of anticancer drug development in which the company operates continues to have substantial unmet needs because clinical treatment outcomes remain unsatisfactory. Global pharmaceutical companies and drug-discovery ventures like the company are competing daily in research and development, seeking to develop innovative new drugs that capitalize on their respective strengths and distinctive capabilities.」
The company continues to identify the significant unmet needs in cancer and competition in research and development among pharmaceutical companies and drug-discovery ventures as part of its business environment. - FY2019-Q3RestatedAnnual report
「The field of anticancer drug development in which the company operates continues to have substantial unmet needs because clinical treatment outcomes remain unsatisfactory. Global pharmaceutical companies and drug-discovery ventures like the company are competing daily in research and development, seeking to develop innovative new drugs that capitalize on their respective strengths and distinctive capabilities.」
The company continues to identify the significant unmet needs in cancer and competition in research and development among pharmaceutical companies and drug-discovery ventures as part of its business environment. - FY2019-Q2RestatedAnnual report
「Against this backdrop, the cancer field, where clinical treatment outcomes have substantial room for improvement, is regarded as one of the promising areas for targeting new drug development, and pharmaceutical companies and biotechnology ventures worldwide are working to strengthen their research and development capabilities.」
The company continues to identify the significant unmet needs in cancer and competition in research and development among pharmaceutical companies and biotechnology ventures as part of its business environment. - FY2019-Q1RestatedAnnual report
「The field of anticancer drug development in which the company operates continues to have substantial unmet needs because clinical treatment outcomes remain unsatisfactory. Global pharmaceutical companies and drug-discovery ventures like the company are competing daily in research and development, seeking to develop innovative new drugs that capitalize on their respective strengths and distinctive capabilities.」
The company continues to identify the significant unmet needs in cancer and competition in research and development among pharmaceutical companies and drug-discovery ventures as part of its business environment. - FY2018-Q3RestatedAnnual report
「The field of anticancer drug development in which the company operates continues to have substantial unmet needs because clinical treatment outcomes remain unsatisfactory. Global pharmaceutical companies and drug-discovery ventures like the company are competing daily in research and development, seeking to develop innovative new drugs that capitalize on their respective strengths and distinctive capabilities.」
The company continues to identify the significant unmet needs in cancer and competition in research and development among pharmaceutical companies and drug-discovery ventures as part of its business environment. - FY2018-Q2RestatedAnnual report
「The field of anticancer drug development in which the company operates continues to have substantial unmet needs because clinical treatment outcomes remain unsatisfactory. Global pharmaceutical companies and drug-discovery ventures like the company are competing daily in research and development, seeking to develop innovative new drugs that capitalize on their respective strengths and distinctive capabilities.」
The company continues to identify the significant unmet needs in cancer and competition in research and development among pharmaceutical companies and drug-discovery ventures as part of its business environment. - FY2017RestatedAnnual report
「The cancer field, where clinical treatment outcomes still have room for improvement, continues to be regarded as one of the promising areas for targeting new drug development, and pharmaceutical companies and biotechnology ventures worldwide are working to strengthen their research and development capabilities.」
The company continues to recognize unmet needs in cancer and competition in drug development among pharmaceutical companies and biotechnology ventures. - FY2017-Q3RestatedAnnual report
「In recent years, the launch of immune checkpoint antibodies has brought about changes in market needs in the cancer field that could be described as a paradigm shift.」
The company continues to recognize the market environment as one characterized by significant unmet needs in cancer and competition in new drug development. - FY2017-Q1First statedAnnual report
「The field of anticancer drug development in which the company operates continues to have substantial unmet needs because clinical treatment outcomes remain unsatisfactory. Global pharmaceutical companies and drug-discovery ventures like the company are competing daily in research and development, seeking to develop innovative new drugs that capitalize on their respective strengths and distinctive capabilities.」
Although cancer has significant unmet medical needs, competition in drug development continues among global pharmaceutical companies and drug-discovery ventures.